Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine

Shih Jiuan Chiu, Naoto T. Ueno, Robert J. Lee

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

A series of novel nonviral vectors targeting the HER-2/neu gene product human epidermal growth factor receptor-2 (HER2) were constructed and evaluated in breast cancer cell lines to optimize vector formulation for receptor-specific gene transfer. These vectors were DNA/polycation complexes (polyplexes) prepared by mixing, at varying ratios, plasmid DNA carrying a luciferase reporter gene to HerPEI, which is a conjugate of linear polyethylenimine (PEI), a cationic polymer, and trastuzumab (Herceptin®), a HER2-specific monoclonal antibody. Transfection studies were carried out in both HER2 overexpressing Sk-Br-3 and HER2 low-expressing MDA-MB-231 breast cancer cells. The HerPEI polyplexes showed significantly greater transfection activity up to 20-folds than nonderivatized PEI-based polyplexes in the Sk-Br-3 cells. The transfection efficiency of targeted polyplexes was dependent on the trastuzumab:PEI ratio and can be blocked by excess free trastuzumab, suggesting HER2-mediated gene delivery. In contrast, no significant difference in transfection activities was observed between HER2-targeted and nontargeted polyplexes in the HER2 low-expressing MDA-MB-231 cells. The transfection efficiency of HerPEI polyplexes was retained in serum-containing medium. In summary, HerPEI polyplexes have shown promising HER2 receptor-specific gene transfer properties and warrant further evaluation as a tumor-targeted vector for gene therapy.

Original languageEnglish
Pages (from-to)357-369
Number of pages13
JournalJournal of Controlled Release
Volume97
Issue number2
DOIs
Publication statusPublished - Jun 18 2004
Externally publishedYes

Fingerprint

Polyethyleneimine
Antibodies
Transfection
Genes
Neoplasms
erbB-2 Genes
Breast Neoplasms
Trastuzumab
human ERBB2 protein
DNA
polycations
Luciferases
Reporter Genes
Genetic Therapy
Polymers
Plasmids
Monoclonal Antibodies
Cell Line

Keywords

  • Drug targeting
  • Gene therapy
  • HER-2/neu
  • HER2 receptor
  • Nonviral gene transfer vectors
  • Polyethylenimine
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine. / Chiu, Shih Jiuan; Ueno, Naoto T.; Lee, Robert J.

In: Journal of Controlled Release, Vol. 97, No. 2, 18.06.2004, p. 357-369.

Research output: Contribution to journalArticle

@article{174f104a6119430c9c6fc14cfecbb5d4,
title = "Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin{\circledR}) conjugated polyethylenimine",
abstract = "A series of novel nonviral vectors targeting the HER-2/neu gene product human epidermal growth factor receptor-2 (HER2) were constructed and evaluated in breast cancer cell lines to optimize vector formulation for receptor-specific gene transfer. These vectors were DNA/polycation complexes (polyplexes) prepared by mixing, at varying ratios, plasmid DNA carrying a luciferase reporter gene to HerPEI, which is a conjugate of linear polyethylenimine (PEI), a cationic polymer, and trastuzumab (Herceptin{\circledR}), a HER2-specific monoclonal antibody. Transfection studies were carried out in both HER2 overexpressing Sk-Br-3 and HER2 low-expressing MDA-MB-231 breast cancer cells. The HerPEI polyplexes showed significantly greater transfection activity up to 20-folds than nonderivatized PEI-based polyplexes in the Sk-Br-3 cells. The transfection efficiency of targeted polyplexes was dependent on the trastuzumab:PEI ratio and can be blocked by excess free trastuzumab, suggesting HER2-mediated gene delivery. In contrast, no significant difference in transfection activities was observed between HER2-targeted and nontargeted polyplexes in the HER2 low-expressing MDA-MB-231 cells. The transfection efficiency of HerPEI polyplexes was retained in serum-containing medium. In summary, HerPEI polyplexes have shown promising HER2 receptor-specific gene transfer properties and warrant further evaluation as a tumor-targeted vector for gene therapy.",
keywords = "Drug targeting, Gene therapy, HER-2/neu, HER2 receptor, Nonviral gene transfer vectors, Polyethylenimine, Trastuzumab",
author = "Chiu, {Shih Jiuan} and Ueno, {Naoto T.} and Lee, {Robert J.}",
year = "2004",
month = "6",
day = "18",
doi = "10.1016/j.jconrel.2004.03.019",
language = "English",
volume = "97",
pages = "357--369",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine

AU - Chiu, Shih Jiuan

AU - Ueno, Naoto T.

AU - Lee, Robert J.

PY - 2004/6/18

Y1 - 2004/6/18

N2 - A series of novel nonviral vectors targeting the HER-2/neu gene product human epidermal growth factor receptor-2 (HER2) were constructed and evaluated in breast cancer cell lines to optimize vector formulation for receptor-specific gene transfer. These vectors were DNA/polycation complexes (polyplexes) prepared by mixing, at varying ratios, plasmid DNA carrying a luciferase reporter gene to HerPEI, which is a conjugate of linear polyethylenimine (PEI), a cationic polymer, and trastuzumab (Herceptin®), a HER2-specific monoclonal antibody. Transfection studies were carried out in both HER2 overexpressing Sk-Br-3 and HER2 low-expressing MDA-MB-231 breast cancer cells. The HerPEI polyplexes showed significantly greater transfection activity up to 20-folds than nonderivatized PEI-based polyplexes in the Sk-Br-3 cells. The transfection efficiency of targeted polyplexes was dependent on the trastuzumab:PEI ratio and can be blocked by excess free trastuzumab, suggesting HER2-mediated gene delivery. In contrast, no significant difference in transfection activities was observed between HER2-targeted and nontargeted polyplexes in the HER2 low-expressing MDA-MB-231 cells. The transfection efficiency of HerPEI polyplexes was retained in serum-containing medium. In summary, HerPEI polyplexes have shown promising HER2 receptor-specific gene transfer properties and warrant further evaluation as a tumor-targeted vector for gene therapy.

AB - A series of novel nonviral vectors targeting the HER-2/neu gene product human epidermal growth factor receptor-2 (HER2) were constructed and evaluated in breast cancer cell lines to optimize vector formulation for receptor-specific gene transfer. These vectors were DNA/polycation complexes (polyplexes) prepared by mixing, at varying ratios, plasmid DNA carrying a luciferase reporter gene to HerPEI, which is a conjugate of linear polyethylenimine (PEI), a cationic polymer, and trastuzumab (Herceptin®), a HER2-specific monoclonal antibody. Transfection studies were carried out in both HER2 overexpressing Sk-Br-3 and HER2 low-expressing MDA-MB-231 breast cancer cells. The HerPEI polyplexes showed significantly greater transfection activity up to 20-folds than nonderivatized PEI-based polyplexes in the Sk-Br-3 cells. The transfection efficiency of targeted polyplexes was dependent on the trastuzumab:PEI ratio and can be blocked by excess free trastuzumab, suggesting HER2-mediated gene delivery. In contrast, no significant difference in transfection activities was observed between HER2-targeted and nontargeted polyplexes in the HER2 low-expressing MDA-MB-231 cells. The transfection efficiency of HerPEI polyplexes was retained in serum-containing medium. In summary, HerPEI polyplexes have shown promising HER2 receptor-specific gene transfer properties and warrant further evaluation as a tumor-targeted vector for gene therapy.

KW - Drug targeting

KW - Gene therapy

KW - HER-2/neu

KW - HER2 receptor

KW - Nonviral gene transfer vectors

KW - Polyethylenimine

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=2942520109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942520109&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2004.03.019

DO - 10.1016/j.jconrel.2004.03.019

M3 - Article

C2 - 15196762

AN - SCOPUS:2942520109

VL - 97

SP - 357

EP - 369

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -